<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867047</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037620</org_study_id>
    <secondary_id>Pro00037620</secondary_id>
    <nct_id>NCT01867047</nct_id>
  </id_info>
  <brief_title>ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients</brief_title>
  <official_title>Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Angiotension Converting Enzyme
      Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients
      undergoing elective total hip or knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following an interim analysis the study team felt that there was enough data that showed no
    significant difference.
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 24, 2016</completion_date>
  <primary_completion_date type="Actual">June 24, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Mild Hypotension</measure>
    <time_frame>From baseline to discharge from hospital (approximately 5 days)</time_frame>
    <description>The number of participants with mild hypotension (Systolic Blood Pressure (SBP) less than 85 mmHG) will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Severe Hypotension</measure>
    <time_frame>From baseline to discharge from hospital (approximately 5 days)</time_frame>
    <description>The number of participants with severe hypotension (Systolic Blood Pressure less than 65 mmHG) will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Given Vasopressors</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <description>The number of participants who received vasopressors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Transferred to Intensive Care Unit (ICU)</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <description>The number of participants transferred to Intensive Care Unit (ICU) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Received Allogeneic Blood</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <description>The number of participants that received allogeneic blood will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Kidney Injury</measure>
    <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
    <description>Number of participants with acute kidney injury will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Adverse Effects of Angiotensin-converting-enzyme Inhibitors</condition>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Continuation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will continue their ACE-I through the day of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cessation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-I Cessation group</intervention_name>
    <description>Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)</description>
    <arm_group_label>Cessation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-I Continuation group</intervention_name>
    <description>Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)</description>
    <arm_group_label>Continuation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients electing to undergo primary or revision total hip or knee arthroplasty

          -  Currently taking an ACE-I

        Exclusion Criteria:

          -  Trauma patients

          -  Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy
             patients, chronic steroid use)

          -  Patients with history of severe hypertension related illness such as hypertension
             associated with stroke or myocardial infarction

          -  Patients in who continuation of their ACE-I is expressly mandated by their prescribing
             physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bolognesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2013</study_first_posted>
  <results_first_submitted>August 30, 2017</results_first_submitted>
  <results_first_submitted_qc>August 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2017</results_first_posted>
  <disposition_first_submitted>June 23, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 13, 2017</disposition_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were prescreened by the study team and then identified and presented to the surgeon during the preoperative clinic visit. Once IRB approval was granted on 8-9-2012 study team started screening the clinic schedule for potential participants.</recruitment_details>
      <pre_assignment_details>Randomization of participants occurred only if the proposed inclusion/exclusion criteria were met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuation Group</title>
          <description>ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
        </group>
        <group group_id="P2">
          <title>Cessation Group</title>
          <description>ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>surgery not indicated in protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Continuation Group</title>
          <description>ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
        </group>
        <group group_id="B2">
          <title>Cessation Group</title>
          <description>ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="10.8"/>
                    <measurement group_id="B2" value="63.7" spread="8.7"/>
                    <measurement group_id="B3" value="63.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Mild Hypotension</title>
        <description>The number of participants with mild hypotension (Systolic Blood Pressure (SBP) less than 85 mmHG) will be recorded.</description>
        <time_frame>From baseline to discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild Hypotension</title>
          <description>The number of participants with mild hypotension (Systolic Blood Pressure (SBP) less than 85 mmHG) will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intraoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for intraoperative mild hypotension</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for postoperative mild hypotension</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Severe Hypotension</title>
        <description>The number of participants with severe hypotension (Systolic Blood Pressure less than 65 mmHG) will be recorded.</description>
        <time_frame>From baseline to discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypotension</title>
          <description>The number of participants with severe hypotension (Systolic Blood Pressure less than 65 mmHG) will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intraoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Given Vasopressors</title>
        <description>The number of participants who received vasopressors.</description>
        <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Given Vasopressors</title>
          <description>The number of participants who received vasopressors.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intraoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for number of participants given vasopressors intraoperatively</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Transferred to Intensive Care Unit (ICU)</title>
        <description>The number of participants transferred to Intensive Care Unit (ICU) will be recorded</description>
        <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Transferred to Intensive Care Unit (ICU)</title>
          <description>The number of participants transferred to Intensive Care Unit (ICU) will be recorded</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Received Allogeneic Blood</title>
        <description>The number of participants that received allogeneic blood will be recorded.</description>
        <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Received Allogeneic Blood</title>
          <description>The number of participants that received allogeneic blood will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Kidney Injury</title>
        <description>Number of participants with acute kidney injury will be recorded.</description>
        <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Kidney Injury</title>
          <description>Number of participants with acute kidney injury will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.700</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Length of Stay</title>
        <description>Length of stay in days</description>
        <time_frame>Discharge from hospital (approximately 5 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Group</title>
            <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)</description>
          </group>
          <group group_id="O2">
            <title>Cessation Group</title>
            <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Length of stay in days</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.702</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to hospital discharge (approximately 5 days)</time_frame>
      <desc>The study team only collected adverse events that were unanticipated and reported to the study coordinator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Continuation Group</title>
          <description>Subjects randomized to this group will continue their ACE-I through the day of surgery
ACE-I Continuation group: Subjects take ACE-I through day of surgery</description>
        </group>
        <group group_id="E2">
          <title>Cessation Group</title>
          <description>Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose &gt;48 hours prior to surgery)
ACE-I Cessation group: Subjects stop ACE-I 48 hours prior to surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this study include a low power, as the investigators assessed a relatively small number of participants, and as such the investigators recommend repeated studies with larger numbers of participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Bolognesi, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <email>michael.bolognesi@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

